New drug combo may replace harsh transplant for hodgkin lymphoma patients

NCT ID NCT05502250

Ongoing Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Mar 09, 2026 · Last updated May 01, 2026 · Updated 10 times

Summary

This study tests a new drug called tislelizumab combined with chemotherapy for people whose Hodgkin lymphoma has returned or not responded to initial treatment. The goal is to see if this approach works as well as the standard intensive chemotherapy and stem cell transplant. About 75 adults will receive the drug combo, and those who achieve complete remission will continue on tislelizumab alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

BE-Bruxelles-STLUC

Brussels, Belgium
DK-Aarhus N-AUH

Aarhus, Denmark
DK-Copenhagen-RIGSHOSPITALET

Copenhagen, Denmark
DK-Odense-OUH

Odense, Denmark
NL-Amersfoort-MEANDERMC

Amersfoort, Netherlands
NL-Amsterdam-AMC

Amsterdam, Netherlands
NL-Arnhem-RIJNSTATE

Arnhem, Netherlands
NL-Den Haag-HAGA

The Hague, Netherlands
NL-Eindhoven-MAXIMAMC

Eindhoven, Netherlands
NL-Goes-ADRZ

Goes, Netherlands
NL-Groningen-UMCG

Groningen, Netherlands
NL-Hoofddorp-SPAARNEGASTHUIS

Hoofddorp, Netherlands
NL-Leeuwarden-MCL

Leeuwarden, Netherlands
NL-Maastricht-MUMC

Maastricht, Netherlands
NL-Rotterdam-ERASMUSMC

Rotterdam, Netherlands

Conditions

Explore the condition pages connected to this study.

HODGKIN LYMPHOMA